CLINICAL TRANSPLANTATION, cilt.28, sa.10, ss.1177-1183, 2014 (SCI-Expanded, Scopus)
BackgroundTacrolimus is a CYP3A4 inhibitor and can alter colchicine metabolism. In this study, we aimed to evaluate plasma colchicine levels in different stages of kidney disease as well as in kidney transplant (KTx) recipients using tacrolimus.